

Global Clinical Trial and Commercialization for Development of Next-generation Long-acting Glucagon (HM15136) for Congenital Hyperinsulinism (CHI)

Hanmi Pharm. Co., Ltd.



METABOLIC	Phase 2
Product Type	Protein Product (Peptide)
Indication	1st indication: Congenital Hyperinsulinism [MeSH term]
Target	-
MoA(Mechanism of Action)	Novel Glucagon Analogue conjugated with human IgG Fc fragment
Competitiveness	New Glucagon Formulation & Long duration of action - Increased solubility to ensure stability / Ready-to-Use Formulation Weekly Dosing Unique clinical positioning - Prevention of Hypoglycemia not Rescue
Development Stage	Phase 2
Route of Administration	Subcutaneous Injection